Wednesday, February 28, 2018 9:24:50 PM
Previous posts:
- Shaanxi Aoxing Pharmaceutical Impact
- Financials For Production Relaunch / Sales Platform
- Consolidation, Low Volume Slide: Rise
After taking the moderator job here, I have updated some sheets with 01 and dropped them in the intro of this board.
- Using 12 month MA for stock price and hence MCAP
- Showing the development of those Deposits and usage, they are real
One probable additional surprise could be the closing of the acquisition of the Health Product Manufacturer, which is about to finalize.
Yes, we do think this company has a lot of potential growth now, especially after restarting production and sales in 2Q18. Hence the intense DD withing the last days. If DD is completed, my posts here will be reduced of course.
We have traded the first rise while waiting for the GMP Certificate, after it was granted we bought more - a lot.
Then slowly sliced it out on the way down.
After Spring Festival was over, we started buying the dips again and will continue to do so over the next sessions.
Medium term price target is above $5, probably $8+.
If production and sales are showing good results, much more is possible here of course.
FEATURED Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • Apr 16, 2024 8:52 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM
Avant Technologies Begins Development on Next-Generation AI-Driven Resource Allocation Solution • AVAI • Apr 16, 2024 8:00 AM
UC Asset Expected to Report $0.03/share Net Profit for 2023 • UCASU • Apr 11, 2024 10:00 AM
